|
Myasthenia Gravis Updates From AAN 2026 - Medscape
Myasthenia gravis updates from AAN 2026 include positive results for cemdisiran, sustained efficacy for nipocalimab, and promising data for a CAR T-cell therapy and the nanobody therapy gefurulimab.
MHRA Approves Nipocalimab for Myasthenia Gravis - Medscape
The MHRA has authorised nipocalimab for generalised myasthenia gravis in adults and adolescents aged 12 and over, based on evidence from two clinical studies.
Is Pregnancy Safe for Women With Myasthenia Gravis? - Medscape
Pregnancy does not increase the risk for exacerbations of myasthenia gravis, but the postpartum period is associated with a higher risk for prolonged hospital stays for exacerbations.
What Test Should Be Used to Diagnose Myasthenia Gravis?
In clinically diagnosed myasthenia gravis, repetitive nerve stimulation has been found to be abnormal in 76% of individuals with more widespread muscle weakness (than observed in ocular ptosis ...
Conference MDAngle: AAN 2026 Myasthenia Gravis - Medscape
Insights from AAN 2026, including anticipated presentations, key takeaways, and how emerging research in myasthenia gravis may affect patient care.
AAN 2026: Redefining Success in Myasthenia Gravis - Medscape
Katherine Ruzhansky, MD, reports on the aftermath of AAN 2026, where data from recent myasthenia gravis (MG) trials reflected an expansion of therapeutic targets and treatment paradigms. The phase ...
AAN 2026: Exploring New Terrain in Myasthenia Gravis Care - Medscape
Dr Katherine Ruzhansky previews updates in MG care, including new data on telitacicept, new findings for efgartigimod, and insights into underrecognized comorbidities.
NICE Recommends First Treatment for Uncontrolled gMG - Medscape
NICE has recommended rozanolixizumab as the first NHS treatment for adults with uncontrolled generalised myasthenia gravis.
AAN 2026: Reflections on a New Era in Myasthenia Gravis - Medscape
In a post-conference reflection, Katherine Ruzhansky, MD, explains how the myasthenia gravis (MG) treatment landscape is rapidly evolving, with multiple novel, targeted therapies such as FcRn ...
Self-Administered Med Shows Promise in Myasthenia Gravis
Weekly subcutaneous gefurulimab delivered early is linked to lasting symptom improvement in patients with generalized myasthenia gravis in phase 3 PREVAIL trial.
|
1000s of New Jobs